capnograph/pulse  oximeter  monitor  is
indications  for  use  in the  predicate  device 
intended  to  provide  professionally
with  the  addition  of the  following: 
trained  health  care  providers  the
The  Capnostream  20  monitor provides 
continuous,  non  invasive
the  clinician  with  an  integrated  pulmonary  measurement  and  monitoring  of
index (IPI).  The  IPI  is based  on four 
parameters  provided  by the  monitor:  end 
tidal  carbon  dioxide,  respiration  rate, 

carbon  dioxide  concentration  of the
expired  and  inspired  breath  and
respiration  rate,  and for the  continuous
non-invasive monitoring  of functional
oxygen  saturation  of arterial
Ihemoglobin  (Sp0 2 and  pulse  rate).  It is

intended  for use  with  neonatal,
pediatric  and adult  patients  in
hospitals,  hospital  type  facilities,  intra
hospital  transport  and  home

environments.

oxygen  saturation  and  heart  rate.  The  IPI 
is a  single  index  of an  adult  or  pediatric 
patient's  ventilatory  status  displayed  on  a 
scale  of 1 - 10,  where  10  indicates 
optimal  pulmonary  status.  IPI  monitoring
displays  a  single  value that  represents
the  patient's  pulmonary  parameters  and
alerts  clinicians  to changes  in the

patient's  pulmonary  status.

The  IPI  is an  adjunct  to,  and  is not
intended  to  replace,  vital  sign  monitoring.

Target 
population 

Design 

Where  Used 

It is intended  for use  with  neonatal, 
pediatric,  and  adult  patients. 

It is intended  for  use  with  neonatal,
pediatric,  and  adult  patients.

Identical  to  the Capnostream  20 
described  in K072295 with  the  exception
of the  software-changes  in both  the
EtCO2  module  and  host  monitor
described  in this submission

See  K072295

It is to  be  used  by  physicians,  nurses  and 
other trained  health  care  providers  in 
critical  care  patient  settings,  such  as 
anesthesiology,  intensive  care  medicine, 
neonatal  intensive  care  and  other  health 
care areas 

It is to  be  used  by  physicians,  nurses
and  other  trained  health  care  providers
in critical  care  patient  settings,  such as
anesthesiology,  intensive  care
medicine,  neonatal  Intensive  care  and
other  health  care  areas

Performance 
Standards 

ISO  21647 
ISO  9919 

ISO  21647
ISO  9919

Safety 
Standards 

IEC/EN  60601-1 
IEC/EN  60601-1-2(2001) 

lEC/EN  60601-1
IEC/EN  60601-1-2(2001)

IEC  60601-1-8 
UL  60601-1 
ISO  14971 

IEC  60601-1-8
UL  60601 -1
ISO  14971

Biocompatibility  There  are  no  issues  of  biocompatibility  for  There  are  no  issues  of biocompatibility
for this  device  and  no  biocompatibility
testing  was  done.

this  device  and  no  biocompatibility  testing 
was  done. 

Sterility 

This  device  does  not require  sterilization 
and  is shipped  marked  non-sterile. 

This  device  does  not  require
sterilization  and  is shipped  marked
non-sterile.

CONCLUSION

Capnostream  20 with  the  IPI functionality  does  not  raise  any  new potential  safety  risks
and  is equivalent  in performance  to the  existing  legally  marketed  device.  Therefore,  the
device  is substantially  equivalent  to the  predicate  device  with  respect  to  safety,
effectiveness,  and  intended  use.

Â·
x

sicv  iCEs'

DEPARTMENT  OF HEALTH  &  HUMAN  SERVICES 

Public  Health  Service

Food  and  Drug  Administration
9200  Corporate  Boulevard
Rockville  MD  20850

FEB  - 9 2009

Ms.  Rachel  Weissbrod
Director  of Regulatory  Affairs
Oridion  Capnography,  Incorporated
c/o  Oridion  Medical  1987  Limited
Har  Hotzvim  Science  Park,  POB  45025
Jerusalem
Israel  91450

Re:  K082268

Trade/Device  Name:  Capnostream20
Regulation  Number:  870.2700
Regulation  Name:  Oximeter
Regulatory  Class:  II
Product  Code:  DQA,  CCK
Dated:  January  9,  2009
Received:  January  27,  2009

Dear  Ms.  Weissbrod:

We  have  reviewed  your  Section  510(k)  premarket  notification  of intent to  market the  device
referenced  above  and  have  determined  the device  is  substantially  equivalent  (for  the
indications  for use  stated  in  the enclosure)  to  legally  marketed  predicate  devices  marketed  in
interstate  commerce  prior to  May  28,  1976,  the  enactment  date  of the Medical  Device
Amendments,  or to  devices  that  have  been  reclassified  in  accordance  with the provisions  of
the  Federal  Food,  Drug, and  Cosmetic  Act (Act)  that  do not require  approval  of a premarket
approval  application  (PMA).  You may,  therefore,  market  the device,  subject  tO  the  general
controls  provisions  of the  Act.  The  general  controls  provisions  of the Act  include
requirements  for annual  registration,  listing of devices,  good  manufacturing  practice,
labeling,  and  prohibitions  against misbranding  and  adulteration.

If your device  is  classified  (see  above)  into  either  class II (Special  Controls)  or  class  III
(PMA),  it  may be  subject  to  such  additional  controls.  Existing major  regulations  affecting
your device  can  be  found  in the  Code  of Federal  Regulations,  Title  21,  Parts  800  to  898.  In
addition,  FDA  may  publish  further  announcements  concerning  your device  in  the  Federal
Register.

Page  2 - Ms.  Weissbrod

Please  be  advised  that  FDA's issuance  of a substantial  Equivalence  determination  does  not
mean  that  FDA  has made  a  determination  that  your device  complies  with  other  requirements
of the  Act  or  any Federal  statutes  and  regulations  administered  by  other Federal  agencies.
You must  comply  with  all  the  Act's  requirements,  including,  but not  limited  to:  registration
and  listing  (21  CFR  Part  807);  labeling  (21  CFR  Part  801);  good manufacturing  practice
requirements  as  set  forth  in  the  quality  systems  (QS)  regulation  (2.1  CFR  Part  820);  and  if
applicable,  the  electronic  product  radiation  control  provisions  (Sections  531-542  of the  Act);
21  CFR  1000-1050.

This  letter will allow you  to  begin  marketing  your  device  as described  in  your  Section  510(k)
premarket  notification.  The FDA  finding  of substantial  equivalence  of your  device  to a
legally  marketed  predicate  device  results  in  a classification  for  your device  and thus,  permits
your  device  to  proceed  to the  market.

If you  desire  specific  advice  for  your device  on  our  labeling  regulation  (21  CFR Part  801),
please  contact  the Center  for  Devices  and  Radiological  Health's  (CDRH's) Office  of
Compliance  at  (240)  276-0120.  Also,  please  note the regulation  entitled,  "Misbranding  by
reference  to  premarket  notification"  (21CFR  Part 807.97).  For  questions  regarding
postmarket  surveillance,  please  contact  CDRH's Office  of Surveillance  and  Biometric's
(OSB's) Division  of Postmarket  Surveillance  at 240-276-3474.  For  questions  regarding  the
reporting  of device  adverse  events  (Medical  Device Reporting  (MDR)),  please  contact the
Division  of Surveillance  Systems  at 240-276-3464.  You may obtain  other  general
information  on your responsibilities  under  the Act from  the  Division  of Small
Manufacturers,  International  and  Consumer  Assistance  at its  toll-free  number  (800)
638-2041  or (240)  276-3150  or  at its Internet  address
http://www.fda.gov/cdrh/industry/support/indexlhtml.

Sincerely yours,

Ginette  Y.  Michaud,  M.D.
Acting Director
Division of Anesthesiology,  General  Hospital,

Infection  Control  and Dental  Devices

Office  of Device Evaluation
Center. for  Devices  and
Radiological  Health

Enclosure

1. Statement of  Indications  for Use

TWO  PARAMETER  CAPNOSTREAM  20  MONITOR WITH  INTEGRATED
PULMONARY  INDEX  (IPI)

(This  document  is  not confidential)
Indications for  Use

August  15,  2008

510(k)  Number  (if known):  K082268

Device  Name:  Capnostream  20

Indications  for Use:
The  Capnostream  20  combined  capnograph/pulse  oximeter  monitor  is intended  to  provide
professionally  trained  health  care  providers  the continuous,  non  invasive  measurement  and
monitoring  of  carbon  dioxide  concentration  of the expired  and  inspired  breath  and  respiration
rate,  and  for the  continuous  non-invasive  monitoring  of functional  oxygen  saturation  of arterial
hemoglobin  (SpO 2) and  pulse  rate.  It is intended  for use  with  neonatal,  pediatric  and  adult
patients  in hospitals,  hospital  type  facilities,  intra  hospital  transport  and  home  environments.

The  Capnostream  20  monitor  provides  the clinician  with  an  integrated  pulmonary  index  (IPI).
The  IPI  is based  on  four  parameters  provided  by  the  monitor:  end tidal carbon  dioxide,
respiration  rate,  oxygen  saturation  and  pulse  rate.  The  IPI  is a  single  index  of an  adult or
pediatric  patient's ventilatory  status displayed  on a  scale  of 1 - 10, where  10  indicates  optimal
pulmonary  status.  IPI  monitoring  displays  a  single  value that  represents  the  patient's  pulmonary
parameters  and  alerts clinicians  to  changes  in the  patient's  pulmonary  status.

The  IPI  is an  adjunct to,  and is  not  intended  to  replace,  vital  sign  monitoring.

Prescription  Use 
(Per 21  CFR  801  Subpart  D) 

X 

AND/OR 

Over-The-Counter  Use

(21  CFR  801  Subpart  C)

PLEASE  DO  NOT  WRITE  BELOW THIS  LINE  - CONTINUE  ON  ANOTHER  PAGE  IF
NEEDED)

(Division Sign-Off)
Division of Anesthesiology,  General  Hospital
Infection  Control,  Dental  Devices

510(k) Number:  1-o  c 

(